Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Ascendis Pharma announces US commercial launch of SKYTROFA » 08:03
10/15/21
10/15
08:03
10/15/21
08:03
ASND

Ascendis Pharma

$160.32 /

-5.59 (-3.37%)

Ascendis Pharma A/S…

Ascendis Pharma A/S announced the U.S. commercial launch of SKYTROFA, its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone. SKYTROFA is available by prescription and distributed through a network of specialty pharmacies across the United States. "SKYTROFA offers patients, caregivers, and physicians the potential to replace daily somatropin injections that have been the standard of care for more than 30 years," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "As the first and only FDA-approved once-weekly therapy for pediatric growth hormone deficiency, SKYTROFA represents one of the most important innovations for these patients in decades." Ascendis Pharma has also launched the Ascendis Signature Access Program, a personalized patient support program in the U.S. to work with families, caregivers, and physicians from decision to treat through long-term therapy adherence. The program is staffed by nurses and offers a full suite of services including, but not limited to, prior authorization support, out of pocket assistance, and training on proper injection procedures. The full commercial launch of SKYTROFA marks an important milestone as the Company continues to deliver on its Vision 3x3 strategic roadmap through 2025 to build a leading global biopharma company by achieving sustainable growth through multiple approaches.

ShowHide Related Items >><<
ASND Ascendis Pharma
$160.32 /

-5.59 (-3.37%)

ASND Ascendis Pharma
$160.32 /

-5.59 (-3.37%)

08/26/21 Credit Suisse
Ascendis Pharma price target raised to $185 from $178 at Credit Suisse
08/26/21 JPMorgan
Ascendis Pharma price target raised to $175 from $172 at JPMorgan
07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
ASND Ascendis Pharma
$160.32 /

-5.59 (-3.37%)

  • 02
    Sep
ASND Ascendis Pharma
$160.32 /

-5.59 (-3.37%)

Hot Stocks
Ascendis Pharma announces U.S. commercial launch of Skytrofa » 08:03
10/15/21
10/15
08:03
10/15/21
08:03
ASND

Ascendis Pharma

$160.32 /

-5.59 (-3.37%)

Ascendis Pharma announced…

Ascendis Pharma announced the U.S. commercial launch of Skytrofa, its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone. Skytrofa is available by prescription and distributed through a network of specialty pharmacies across the United States.

ShowHide Related Items >><<
ASND Ascendis Pharma
$160.32 /

-5.59 (-3.37%)

ASND Ascendis Pharma
$160.32 /

-5.59 (-3.37%)

08/26/21 Credit Suisse
Ascendis Pharma price target raised to $185 from $178 at Credit Suisse
08/26/21 JPMorgan
Ascendis Pharma price target raised to $175 from $172 at JPMorgan
07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
ASND Ascendis Pharma
$160.32 /

-5.59 (-3.37%)

  • 02
    Sep
ASND Ascendis Pharma
$160.32 /

-5.59 (-3.37%)

Over a week ago
Hot Stocks
Ascendis Pharma announces $25M share repurchase plan » 16:07
09/29/21
09/29
16:07
09/29/21
16:07
ASND

Ascendis Pharma

$157.07 /

-2.81 (-1.76%)

Ascendis Pharma …

Ascendis Pharma announced that its Board of Directors has authorized the Company to repurchase up to $25M of the Company's American Depositary Shares , each of which represents one ordinary share of Ascendis Pharma A/S. The program will be executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations.

ShowHide Related Items >><<
ASND Ascendis Pharma
$157.07 /

-2.81 (-1.76%)

ASND Ascendis Pharma
$157.07 /

-2.81 (-1.76%)

08/26/21 Credit Suisse
Ascendis Pharma price target raised to $185 from $178 at Credit Suisse
08/26/21 JPMorgan
Ascendis Pharma price target raised to $175 from $172 at JPMorgan
07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
ASND Ascendis Pharma
$157.07 /

-2.81 (-1.76%)

  • 02
    Sep
ASND Ascendis Pharma
$157.07 /

-2.81 (-1.76%)

Over a month ago
Hot Stocks
Ascendis Pharma submits IND application to initiate TransCon IL-2 program » 17:00
09/07/21
09/07
17:00
09/07/21
17:00
ASND

Ascendis Pharma

$164.17 /

-3 (-1.79%)

Ascendis Pharma announced…

Ascendis Pharma announced the submission of an investigational new drug application with the U.S. Food & Drug Administration to initiate IL betaeliegammae Trial, a phase 1/2 clinical trial to evaluate TransCon IL-2 beta/gamma in patients with advanced cancer. TransCon IL-2 beta/gamma is an investigational long-acting prodrug designed to improve cancer immunotherapy by sustained exposure to an IL-2 variant that selectively activates the IL-2Rbeta/gamma, with minimal binding to IL-2Ralpha. "This IND submission for our second clinical stage oncology product candidate represents another major milestone for Ascendis. Our understanding of the biology has guided us in designing a novel parent drug, which we have combined with our clinically validated TransCon platform. We believe this combination has the potential to overcome the known shortcomings of current IL-2 compounds, such as low potency, short half-life and high Cmax. By solving the different elements related to efficacy and safety independently, we believe it will be possible to realize the full potential of the IL-2 pathway and create a potentially best-in-class cancer immunotherapy product," said Kennett Sprogoe, Ph.D., Ascendis Pharma's Head of Innovation and Research.

ShowHide Related Items >><<
ASND Ascendis Pharma
$164.17 /

-3 (-1.79%)

ASND Ascendis Pharma
$164.17 /

-3 (-1.79%)

08/26/21 Credit Suisse
Ascendis Pharma price target raised to $185 from $178 at Credit Suisse
08/26/21 JPMorgan
Ascendis Pharma price target raised to $175 from $172 at JPMorgan
07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
ASND Ascendis Pharma
$164.17 /

-3 (-1.79%)

  • 02
    Sep
ASND Ascendis Pharma
$164.17 /

-3 (-1.79%)

Syndicate
Ascendis Pharma 2.5M share Secondary priced at $160.00 » 19:52
09/01/21
09/01
19:52
09/01/21
19:52
ASND

Ascendis Pharma

$166.05 /

+9.47 (+6.05%)

The deal priced below…

The deal priced below last closing price of $165.72. JPMorgan, Morgan Stanley, Evercore ISI and SVB Leerink are acting as joint book running managers for the offering.

ShowHide Related Items >><<
ASND Ascendis Pharma
$166.05 /

+9.47 (+6.05%)

ASND Ascendis Pharma
$166.05 /

+9.47 (+6.05%)

08/26/21 Credit Suisse
Ascendis Pharma price target raised to $185 from $178 at Credit Suisse
08/26/21 JPMorgan
Ascendis Pharma price target raised to $175 from $172 at JPMorgan
07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
ASND Ascendis Pharma
$166.05 /

+9.47 (+6.05%)

  • 02
    Sep
ASND Ascendis Pharma
$166.05 /

+9.47 (+6.05%)

On The Fly
Fly Intel: After-Hours Movers » 19:00
08/31/21
08/31
19:00
08/31/21
19:00
PLAN

Anaplan

$59.95 /

-1.45 (-2.36%)

, PVH

PVH Corp.

$104.80 /

-1.94 (-1.82%)

, CAL

Caleres

$24.52 /

-0.32 (-1.29%)

, AMBA

Ambarella

$103.61 /

-1.69 (-1.60%)

, TEVA

Teva

$9.42 /

+0.02 (+0.21%)

, PLTK

Playtika

$26.39 /

-0.15 (-0.57%)

, CRWD

Crowdstrike

$280.75 /

-5.73 (-2.00%)

, ASND

Ascendis Pharma

$156.58 /

+1.82 (+1.18%)

, PLBY

PLBY Group

$24.87 /

+0.46 (+1.88%)

Check out this evening's…

ShowHide Related Items >><<
TEVA Teva
$9.42 /

+0.02 (+0.21%)

PVH PVH Corp.
$104.80 /

-1.94 (-1.82%)

PLTK Playtika
$26.39 /

-0.15 (-0.57%)

PLBY PLBY Group
$24.87 /

+0.46 (+1.88%)

PLAN Anaplan
$59.95 /

-1.45 (-2.36%)

CRWD Crowdstrike
$280.75 /

-5.73 (-2.00%)

CAL Caleres
$24.52 /

-0.32 (-1.29%)

ASND Ascendis Pharma
$156.58 /

+1.82 (+1.18%)

AMBA Ambarella
$103.61 /

-1.69 (-1.60%)

PLAN Anaplan
$59.95 /

-1.45 (-2.36%)

08/03/21 Barclays
Anaplan upgraded to Overweight from Equal Weight at Barclays
07/23/21 Loop Capital
Anaplan upgraded to Hold from Sell at Loop Capital
07/15/21 KeyBanc
Anaplan price target raised to $60 from $55 at KeyBanc
06/07/21 Gordon Haskett
Gordon Haskett places Anaplan 'on watch for activism'
PVH PVH Corp.
$104.80 /

-1.94 (-1.82%)

07/14/21 Goldman Sachs
PVH Corp. initiated with a Buy at Goldman Sachs
06/08/21 Citi
PVH Corp. price target raised to $118 from $112 at Citi
06/04/21 RBC Capital
PVH Corp. price target raised to $112 from $106 at RBC Capital
06/04/21 Morgan Stanley
PVH Corp. price target raised to $123 from $114 at Morgan Stanley
CAL Caleres
$24.52 /

-0.32 (-1.29%)

06/01/21 Loop Capital
Caleres price target raised to $30 from $25 at Loop Capital
06/01/21 CL King
Caleres upgraded to Buy from Neutral at CL King
11/20/20 Loop Capital
Caleres price target raised to $20 from $15 at Loop Capital
AMBA Ambarella
$103.61 /

-1.69 (-1.60%)

06/02/21 Roth Capital
Ambarella price target lowered to $130 from $150 at Roth Capital
06/02/21 Stifel
Ambarella price target raised to $140 from $135 at Stifel
03/22/21
Fly Intel: Top five analyst initiations
03/22/21 Wells Fargo
Ambarella initiated with an Equal Weight at Wells Fargo
TEVA Teva
$9.42 /

+0.02 (+0.21%)

06/22/21 JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
05/04/21 UBS
Teva downgraded to Neutral from Buy at UBS
04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
PLTK Playtika
$26.39 /

-0.15 (-0.57%)

08/05/21 Cowen
Playtika valuation remains extremely attractive, says Cowen
06/30/21 Morgan Stanley
Morgan Stanley double downgrades overvalued AppLovin to Underweight
03/25/21 MKM Partners
MKM Partners starts Playtika with a Buy on 'solid' mobile gaming portfolio
03/24/21 MKM Partners
Playtika initiated with a Buy at MKM Partners
CRWD Crowdstrike
$280.75 /

-5.73 (-2.00%)

08/30/21 BofA
Crowdstrike price target raised to $315 from $285 at BofA
08/30/21 Needham
Crowdstrike price target raised to $335 from $277 at Needham
08/30/21 RBC Capital
Crowdstrike price target raised to $300 from $259 at RBC Capital
08/30/21 Barclays
Crowdstrike price target raised to $320 from $240 at Barclays
ASND Ascendis Pharma
$156.58 /

+1.82 (+1.18%)

08/26/21 Credit Suisse
Ascendis Pharma price target raised to $185 from $178 at Credit Suisse
08/26/21 JPMorgan
Ascendis Pharma price target raised to $175 from $172 at JPMorgan
07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
PLBY PLBY Group
$24.87 /

+0.46 (+1.88%)

08/11/21 Roth Capital
PLBY Group price target lowered to $45 from $55 at Roth Capital
06/24/21 Stifel
PLBY Group initiated with a Buy at Stifel
06/14/21 Canaccord
PLBY Group model updated following capital raise events, says Canaccord
05/13/21 Craig-Hallum
PLBY Group price target raised to $50 from $35 at Craig-Hallum
TEVA Teva
$9.42 /

+0.02 (+0.21%)

PVH PVH Corp.
$104.80 /

-1.94 (-1.82%)

PLTK Playtika
$26.39 /

-0.15 (-0.57%)

PLBY PLBY Group
$24.87 /

+0.46 (+1.88%)

PLAN Anaplan
$59.95 /

-1.45 (-2.36%)

CRWD Crowdstrike
$280.75 /

-5.73 (-2.00%)

CAL Caleres
$24.52 /

-0.32 (-1.29%)

ASND Ascendis Pharma
$156.58 /

+1.82 (+1.18%)

AMBA Ambarella
$103.61 /

-1.69 (-1.60%)

  • 02
    Sep
  • 10
    Jun
  • 15
    Jan
TEVA Teva
$9.42 /

+0.02 (+0.21%)

PLBY PLBY Group
$24.87 /

+0.46 (+1.88%)

CRWD Crowdstrike
$280.75 /

-5.73 (-2.00%)

TEVA Teva
$9.42 /

+0.02 (+0.21%)

PVH PVH Corp.
$104.80 /

-1.94 (-1.82%)

PLTK Playtika
$26.39 /

-0.15 (-0.57%)

PLBY PLBY Group
$24.87 /

+0.46 (+1.88%)

PLAN Anaplan
$59.95 /

-1.45 (-2.36%)

CRWD Crowdstrike
$280.75 /

-5.73 (-2.00%)

CAL Caleres
$24.52 /

-0.32 (-1.29%)

ASND Ascendis Pharma
$156.58 /

+1.82 (+1.18%)

AMBA Ambarella
$103.61 /

-1.69 (-1.60%)

TEVA Teva
$9.42 /

+0.02 (+0.21%)

PVH PVH Corp.
$104.80 /

-1.94 (-1.82%)

PLBY PLBY Group
$24.87 /

+0.46 (+1.88%)

PLAN Anaplan
$59.95 /

-1.45 (-2.36%)

CRWD Crowdstrike
$280.75 /

-5.73 (-2.00%)

AMBA Ambarella
$103.61 /

-1.69 (-1.60%)

Syndicate
Ascendis Pharma files to sell $400M of ADSs » 16:01
08/31/21
08/31
16:01
08/31/21
16:01
ASND

Ascendis Pharma

$156.93 /

+2.17 (+1.40%)

J.P. Morgan Securities…

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group L.L.C. and SVB Leerink LLC are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
ASND Ascendis Pharma
$156.93 /

+2.17 (+1.40%)

ASND Ascendis Pharma
$156.93 /

+2.17 (+1.40%)

08/26/21 Credit Suisse
Ascendis Pharma price target raised to $185 from $178 at Credit Suisse
08/26/21 JPMorgan
Ascendis Pharma price target raised to $175 from $172 at JPMorgan
07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
ASND Ascendis Pharma
$156.93 /

+2.17 (+1.40%)

ASND Ascendis Pharma
$156.93 /

+2.17 (+1.40%)

Recommendations
Ascendis Pharma price target raised to $185 from $178 at Credit Suisse » 08:16
08/26/21
08/26
08:16
08/26/21
08:16
ASND

Ascendis Pharma

$122.67 /

+1.235 (+1.02%)

Credit Suisse analyst…

Credit Suisse analyst Tiago Fauth raised the firm's price target on Ascendis Pharma to $185 from $178 and keeps an Outperform rating on the shares. The analyst notes Ascendis announced FDA approval of Skytrofa in pediatric growth hormone deficiency. The label looks consistent with Fauth's expectations - there are no explicit superiority claims over daily growth hormone, which was expected by some investors.

ShowHide Related Items >><<
ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

08/26/21 JPMorgan
Ascendis Pharma price target raised to $175 from $172 at JPMorgan
07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
06/14/21 SVB Leerink
Ascendis Pharma price target lowered to $181 from $191 at SVB Leerink
ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

Recommendations
Ascendis Pharma price target raised to $175 from $172 at JPMorgan » 07:36
08/26/21
08/26
07:36
08/26/21
07:36
ASND

Ascendis Pharma

$122.67 /

+1.235 (+1.02%)

JPMorgan analyst Jessica…

JPMorgan analyst Jessica Fye raised the firm's price target on Ascendis Pharma to $175 from $172 and keeps an Overweight rating on the shares following the approval of Skytrofa. The analyst continues to see a "very compelling entry point" in the shares at current levels and would be a buyer "heading into multiple catalysts ahead." Fye expects the ongoing Phase III PaTHway trial for TransCon PTH to read out in Q1 of 2022.

ShowHide Related Items >><<
ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
06/14/21 SVB Leerink
Ascendis Pharma price target lowered to $181 from $191 at SVB Leerink
06/14/21 Canaccord
Ascendis Pharma PDUFA extension an encouraging sign, says Canaccord
ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

On The Fly
Fly Intel: After-Hours Movers » 18:50
08/25/21
08/25
18:50
08/25/21
18:50
ASND

Ascendis Pharma

$122.67 /

+1.235 (+1.02%)

, ZUO

Zuora

$16.31 /

-0.06 (-0.37%)

, WSM

Williams-Sonoma

$170.50 /

+0.84 (+0.50%)

, PSTG

Pure Storage

$20.96 /

+0.28 (+1.35%)

, ULTA

Ulta Beauty

$389.51 /

+15.86 (+4.24%)

, NTAP

NetApp

$82.14 /

+1.36 (+1.68%)

, SNOW

Snowflake

$283.55 /

+2.13 (+0.76%)

, CRM

Salesforce

$261.35 /

+1.8 (+0.69%)

, SPLK

Splunk

$155.03 /

+2.03 (+1.33%)

, ESTC

Elastic

$158.03 /

-0.57 (-0.36%)

, KOPN

Kopin

$5.42 /

-0.02 (-0.37%)

, SLQT

SelectQuote

$14.35 /

+0.095 (+0.67%)

, LCI

Lannett

$4.09 /

-0.315 (-7.16%)

, ADSK

Autodesk

$342.16 /

+1.11 (+0.33%)

, AVNW

Aviat Networks

$38.60 /

-0.61 (-1.56%)

, GES

Guess

$24.17 /

-0.29 (-1.19%)

, BOX

Box

$25.64 /

-0.21 (-0.81%)

Check out this evening's…

ShowHide Related Items >><<
ZUO Zuora
$16.31 /

-0.06 (-0.37%)

WSM Williams-Sonoma
$170.50 /

+0.84 (+0.50%)

ULTA Ulta Beauty
$389.51 /

+15.86 (+4.24%)

SPLK Splunk
$155.03 /

+2.03 (+1.33%)

SNOW Snowflake
$283.55 /

+2.13 (+0.76%)

SLQT SelectQuote
$14.35 /

+0.095 (+0.67%)

PSTG Pure Storage
$20.96 /

+0.28 (+1.35%)

NTAP NetApp
$82.14 /

+1.36 (+1.68%)

LCI Lannett
$4.09 /

-0.315 (-7.16%)

KOPN Kopin
$5.42 /

-0.02 (-0.37%)

GES Guess
$24.17 /

-0.29 (-1.19%)

ESTC Elastic
$158.03 /

-0.57 (-0.36%)

CRM Salesforce
$261.35 /

+1.8 (+0.69%)

BOX Box
$25.64 /

-0.21 (-0.81%)

AVNW Aviat Networks
$38.60 /

-0.61 (-1.56%)

ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

ADSK Autodesk
$342.16 /

+1.11 (+0.33%)

ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

07/27/21 Wedbush
Ascendis Pharma removed from Best Ideas List at Wedbush
07/08/21 Canaccord
Ascendis Pharma recent selloff a buying opportunity, says Canaccord
06/14/21 SVB Leerink
Ascendis Pharma price target lowered to $181 from $191 at SVB Leerink
06/14/21 Canaccord
Ascendis Pharma PDUFA extension an encouraging sign, says Canaccord
ZUO Zuora
$16.31 /

-0.06 (-0.37%)

04/13/21 Canaccord
Zuora price target raised to $20 from $19 at Canaccord
04/13/21 Jefferies
Zuora market cap could increase to $3B from $2B, says Jefferies
04/08/21 Berenberg
Zuora initiated with a Buy at Berenberg
02/24/21 Jefferies
Zuora price target raised to $17 from $13 at Jefferies
WSM Williams-Sonoma
$170.50 /

+0.84 (+0.50%)

07/22/21
Fly Intel: Top five analyst downgrades
07/22/21 Goldman Sachs
Williams-Sonoma downgraded to Sell from Neutral at Goldman Sachs
07/16/21 Exane BNP Paribas
Williams-Sonoma initiated with a Neutral at Exane BNP Paribas
06/01/21
Fly Intel: Top five analyst upgrades
PSTG Pure Storage
$20.96 /

+0.28 (+1.35%)

08/20/21 Evercore ISI
Pure Storage added to Tactical Outperform List at Evercore ISI
05/27/21 Raymond James
Pure Storage price target raised to $31 from $30 at Raymond James
05/21/21 Stifel
Pure Storage upgraded to Buy from Hold at Stifel
05/13/21 Evercore ISI
Evercore upgrades Pure Storage on 'unique and transient opportunity'
ULTA Ulta Beauty
$389.51 /

+15.86 (+4.24%)

08/24/21 Deutsche Bank
Ulta Beauty price target raised to $417 from $410 at Deutsche Bank
08/23/21 Piper Sandler
Ulta Beauty price target raised to $405 from $386 at Piper Sandler
08/20/21 JPMorgan
Ulta Beauty removed from Analyst Focus List at JPMorgan
08/18/21 Loop Capital
Ulta Beauty price target raised to $360 from $340 at Loop Capital
NTAP NetApp
$82.14 /

+1.36 (+1.68%)

08/19/21 Fox Advisors
NetApp downgraded to Equal Weight from Overweight at Fox Advisors
06/25/21 Raymond James
NetApp upgraded to Outperform from Market Perform at Raymond James
06/25/21 Raymond James
NetApp upgraded to Outperform from Market Perform at Raymond James
06/10/21 Morgan Stanley
Seagate, Dell, NCR, NetApp top picks in IT Hardware at Morgan Stanley
SNOW Snowflake
$283.55 /

+2.13 (+0.76%)

08/23/21 Rosenblatt
Snowflake price target raised to $295 from $265 at Rosenblatt
08/20/21 Piper Sandler
Snowflake selloff on growth concerns overdone, says Piper Sandler
07/06/21 Cowen
Cowen starts Monday.com at Outperform, cites high growth rate
06/14/21 Deutsche Bank
Snowflake price target raised to $265 from $248 at Deutsche Bank
CRM Salesforce
$261.35 /

+1.8 (+0.69%)

08/23/21 Barclays
Salesforce price target raised to $291 from $285 at Barclays
08/18/21 JMP Securities
Salesforce price target raised to $320 from $282 at JMP Securities
07/16/21 Stifel
Salesforce transferred with Buy rating at Stifel
07/12/21 Summit Insights
UiPath initiated with a Sell at Summit Insights
SPLK Splunk
$155.03 /

+2.03 (+1.33%)

08/11/21
Fly Intel: Top five analyst upgrades
08/11/21 UBS
Splunk upgraded to Buy from Neutral at UBS
08/11/21 UBS
Splunk upgraded to Buy from Neutral at UBS
06/25/21 Arete
Splunk upgraded to Buy from Sell at Arete
ESTC Elastic
$158.03 /

-0.57 (-0.36%)

07/13/21 Jefferies
Elastic price target raised to $175 from $150 at Jefferies
07/09/21 Piper Sandler
Elastic price target raised to $175 from $165 at Piper Sandler
06/20/21 Summit Insights
Elastic initiated with a Buy at Summit Insights
06/03/21 Jefferies
Elastic price target raised to $150 from $135 at Jefferies
KOPN Kopin
$5.42 /

-0.02 (-0.37%)

03/03/21 Ladenburg
Kopin price target raised to $12 from $5.50 at Ladenburg
03/03/21 H.C. Wainwright
Kopin downgraded to Neutral from Buy at H.C. Wainwright
01/11/21 H.C. Wainwright
Kopin price target raised to $3.50 from $2 at H.C. Wainwright
SLQT SelectQuote
$14.35 /

+0.095 (+0.67%)

05/21/21 Piper Sandler
SelectQuote recent weakness a buying opportunity, says Piper Sandler
05/13/21 Truist
GoHealth price target lowered to $20 from $26 at Truist
05/12/21 Piper Sandler
SelectQuote should be bought on any guidance selloff, says Piper Sandler
04/06/21 Piper Sandler
SelectQuote assumed with an Overweight at Piper Sandler
LCI Lannett
$4.09 /

-0.315 (-7.16%)

02/04/21 Roth Capital
Roth Capital lowers Lannett target to $7.50 following 'challenging' quarter
08/27/20 Roth Capital
Lannett price target lowered to $9 from $11 at Roth Capital
ADSK Autodesk
$342.16 /

+1.11 (+0.33%)

08/24/21 Barclays
Autodesk price target raised to $370 from $340 at Barclays
08/23/21 RBC Capital
Autodesk price target raised to $363 from $340 at RBC Capital
08/19/21 Morgan Stanley
Autodesk resumed with an Equal Weight at Morgan Stanley
08/19/21 KeyBanc
Autodesk price target raised to $365 from $345 at KeyBanc
AVNW Aviat Networks
$38.60 /

-0.61 (-1.56%)

08/24/21 Roth Capital
Aviat Networks initiated with a Buy at Roth Capital
07/22/21
Fly Intel: Top five analyst initiations
07/22/21 B. Riley
B. Riley starts 'pure wireless play' Aviat with Buy, $50 target
07/21/21 B. Riley
Aviat Networks initiated with a Buy at B. Riley
GES Guess
$24.17 /

-0.29 (-1.19%)

06/23/21 Jefferies
Guess pulled forward earnings target by one year, says Jefferies
05/28/21 B. Riley
Guess price target raised to $38 from $33 at B. Riley
05/19/21 B. Riley
Guess price target raised to $33 from $29 at B. Riley
04/01/21 B. Riley
Guess price target raised to $29 from $27 at B. Riley Securities
BOX Box
$25.64 /

-0.21 (-0.81%)

07/21/21 RBC Capital
Box initiated with an Underperform at RBC Capital
04/09/21 DA Davidson
Box price target lowered to $22 from $25 at DA Davidson
04/09/21 William Blair
KKR investment 'strong vote of confidence' in Box, says William Blair
04/09/21 William Blair
KKR investment 'strong vote of confidence' in Box, says William Blair
ZUO Zuora
$16.31 /

-0.06 (-0.37%)

WSM Williams-Sonoma
$170.50 /

+0.84 (+0.50%)

ULTA Ulta Beauty
$389.51 /

+15.86 (+4.24%)

SPLK Splunk
$155.03 /

+2.03 (+1.33%)

SNOW Snowflake
$283.55 /

+2.13 (+0.76%)

SLQT SelectQuote
$14.35 /

+0.095 (+0.67%)

PSTG Pure Storage
$20.96 /

+0.28 (+1.35%)

NTAP NetApp
$82.14 /

+1.36 (+1.68%)

LCI Lannett
$4.09 /

-0.315 (-7.16%)

KOPN Kopin
$5.42 /

-0.02 (-0.37%)

GES Guess
$24.17 /

-0.29 (-1.19%)

ESTC Elastic
$158.03 /

-0.57 (-0.36%)

CRM Salesforce
$261.35 /

+1.8 (+0.69%)

BOX Box
$25.64 /

-0.21 (-0.81%)

AVNW Aviat Networks
$38.60 /

-0.61 (-1.56%)

ASND Ascendis Pharma
$122.67 /

+1.235 (+1.02%)

ADSK Autodesk
$342.16 /

+1.11 (+0.33%)

  • 16
    Mar
  • 04
    Mar
  • 16
    Sep
SPLK Splunk
$155.03 /

+2.03 (+1.33%)

GES Guess
$24.17 /

-0.29 (-1.19%)

CRM Salesforce
$261.35 /

+1.8 (+0.69%)

BOX Box
$25.64 /

-0.21 (-0.81%)

ADSK Autodesk
$342.16 /

+1.11 (+0.33%)

ZUO Zuora
$16.31 /

-0.06 (-0.37%)

WSM Williams-Sonoma
$170.50 /

+0.84 (+0.50%)

ULTA Ulta Beauty
$389.51 /

+15.86 (+4.24%)

SPLK Splunk
$155.03 /

+2.03 (+1.33%)

SNOW Snowflake
$283.55 /

+2.13 (+0.76%)

SLQT SelectQuote
$14.35 /

+0.095 (+0.67%)

PSTG Pure Storage
$20.96 /

+0.28 (+1.35%)

NTAP NetApp
$82.14 /

+1.36 (+1.68%)

GES Guess
$24.17 /

-0.29 (-1.19%)

ESTC Elastic
$158.03 /

-0.57 (-0.36%)

CRM Salesforce
$261.35 /

+1.8 (+0.69%)

BOX Box
$25.64 /

-0.21 (-0.81%)

ADSK Autodesk
$342.16 /

+1.11 (+0.33%)

WSM Williams-Sonoma
$170.50 /

+0.84 (+0.50%)

ULTA Ulta Beauty
$389.51 /

+15.86 (+4.24%)

SPLK Splunk
$155.03 /

+2.03 (+1.33%)

SNOW Snowflake
$283.55 /

+2.13 (+0.76%)

PSTG Pure Storage
$20.96 /

+0.28 (+1.35%)

NTAP NetApp
$82.14 /

+1.36 (+1.68%)

LCI Lannett
$4.09 /

-0.315 (-7.16%)

KOPN Kopin
$5.42 /

-0.02 (-0.37%)

GES Guess
$24.17 /

-0.29 (-1.19%)

CRM Salesforce
$261.35 /

+1.8 (+0.69%)

BOX Box
$25.64 /

-0.21 (-0.81%)

AVNW Aviat Networks
$38.60 /

-0.61 (-1.56%)

ADSK Autodesk
$342.16 /

+1.11 (+0.33%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.